Inhaled granulocyte-macrophage colony stimulating factor for mild-to-moderate autoimmune pulmonary alveolar proteinosis - a six month phase II randomized study with 24 months of follow-up

Table 3 The primary end point results in the 18 months observational periods after 6 months inhaled GM-CSF treatment

	9 months			12 months			18 months			24 months
	Control group (n = 12)	Treatment group (n = 14)	P value	Control group (n = 13)	Treatment group (n = 14)	P value	Control group (n = 12)	Treatment group (n = 13)	P value	Control group (n = 11)	Treatment group (n = 15)	P value
Δ A-aDO₂ (mmHg)	4.53 ± 7.59	8.11 ± 10.89	0.461	5.19 ± 9.72	7.02 ± 12.35	0.674	8.13 ± 15.02	7.39 ± 8.677	0.579	6.05 ± 11.14	6.61 ± 10.64	0.899
A-aDO₂ (mmHg)	25.24 ± 7.05	22.16 ± 9.09	0.366	22.35 ± 6.54	23.25 ± 8.10	0.756	18.38 ± 10.50	22.24 ± 9.43	0.343	23.72 ± 9.41	23.66 ± 8.96	0.988
Δ PaO₂ (mmHg)	4.29 ± 8.38	7.45 ± 11.82	0.267	2.78 ± 11.41	5.89 ± 11.91	0.496	8.13 ± 15.02	7.71 ± 8.72	0.931	6.16 ± 9.88	4.76 ± 10.72	0.741
PaO₂ (mmHg)	81.08 ± 7.14	84.15 ± 8.93	0.362	81.84 ±7.13	82.59 ± 7.70	0.794	86.48 ± 10.75	84.99 ± 9.76	0.721	82.95 ± 8.05	81.46 ± 10.84	0.707

ISSN: 1750-1172